Simvastatin therapy for drug repositioning to reduce the risk of prostate cancer mortality in patients with hyperlipidemia

Yu An Chen, Ying Ju Lin, Cheng Li Lin, Hwai Jeng Lin, Hua Shan Wu, Hui Ying Hsu, Yu Chen Sun, Hui Yu Wu, Chih Ho Lai, Chia Hung Kao

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Prostate cancer (PCa) is one of the most commonly diagnosed cancers in the western world, and the mortality rate from PCa in Asia has been increasing recently. Statins are potent inhibitors of 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase and are commonly used for treating hyperlipidemia, with beneficial effects for cardiovascular disease and they also exhibit anti-cancer activity. However, the protective effects of statins against PCa are controversial. In this study, we investigated the effect of two types of statins (simvastatin and lovastatin) and the mortality rate of PCa patients by using the Taiwan National Health Insurance Research Database (NHIRD). A total of 15,264 PCa patients with hyperlipidemia records and medical claims from the Registry of Catastrophic Illness were enrolled. The patients were divided into two cohorts based on their statin use before the diagnosis of PCa: statin users (n = 1,827) and non-statin users (n = 1,826). The results showed that patients who used statins exhibited a significantly reduced risk of mortality from PCa [adjusted hazard ratio (HR) = 0.84, 95% CI = 0.73-0.97]. Analysis of the cumulative defined daily dose (DDD) indicated that patients who were prescribed simvastatin = 180 DDD had a dramatically decreased risk of death from PCa (adjusted HR = 0.63; 95% CI = 0.51-0.77). This population-based cohort study demonstrated that statin use significantly decreased the mortality of PCa patients, and that this risk was inversely associated with the cumulative DDD of simvastatin therapy. The results of this study revealed that statins may be used for drug repositioning and in the development of a feasible approach to prevent death from PCa.

Original languageEnglish
Article number225
JournalFrontiers in Pharmacology
Volume9
Issue numberMAR
DOIs
Publication statusPublished - Mar 22 2018

Fingerprint

Drug Repositioning
Simvastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hyperlipidemias
Prostatic Neoplasms
Mortality
Therapeutics
Catastrophic Illness
Lovastatin
Western World
National Health Programs
Taiwan
Medical Records
Registries
Neoplasms
Oxidoreductases
Cohort Studies
Cardiovascular Diseases

Keywords

  • Cohort study
  • HMG-CoA reductase
  • Hyperlipidemia
  • Prostate cancer
  • Statin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Simvastatin therapy for drug repositioning to reduce the risk of prostate cancer mortality in patients with hyperlipidemia. / Chen, Yu An; Lin, Ying Ju; Lin, Cheng Li; Lin, Hwai Jeng; Wu, Hua Shan; Hsu, Hui Ying; Sun, Yu Chen; Wu, Hui Yu; Lai, Chih Ho; Kao, Chia Hung.

In: Frontiers in Pharmacology, Vol. 9, No. MAR, 225, 22.03.2018.

Research output: Contribution to journalArticle

Chen, Yu An ; Lin, Ying Ju ; Lin, Cheng Li ; Lin, Hwai Jeng ; Wu, Hua Shan ; Hsu, Hui Ying ; Sun, Yu Chen ; Wu, Hui Yu ; Lai, Chih Ho ; Kao, Chia Hung. / Simvastatin therapy for drug repositioning to reduce the risk of prostate cancer mortality in patients with hyperlipidemia. In: Frontiers in Pharmacology. 2018 ; Vol. 9, No. MAR.
@article{4a99220ab275494dada371c0d03b76cb,
title = "Simvastatin therapy for drug repositioning to reduce the risk of prostate cancer mortality in patients with hyperlipidemia",
abstract = "Prostate cancer (PCa) is one of the most commonly diagnosed cancers in the western world, and the mortality rate from PCa in Asia has been increasing recently. Statins are potent inhibitors of 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase and are commonly used for treating hyperlipidemia, with beneficial effects for cardiovascular disease and they also exhibit anti-cancer activity. However, the protective effects of statins against PCa are controversial. In this study, we investigated the effect of two types of statins (simvastatin and lovastatin) and the mortality rate of PCa patients by using the Taiwan National Health Insurance Research Database (NHIRD). A total of 15,264 PCa patients with hyperlipidemia records and medical claims from the Registry of Catastrophic Illness were enrolled. The patients were divided into two cohorts based on their statin use before the diagnosis of PCa: statin users (n = 1,827) and non-statin users (n = 1,826). The results showed that patients who used statins exhibited a significantly reduced risk of mortality from PCa [adjusted hazard ratio (HR) = 0.84, 95{\%} CI = 0.73-0.97]. Analysis of the cumulative defined daily dose (DDD) indicated that patients who were prescribed simvastatin = 180 DDD had a dramatically decreased risk of death from PCa (adjusted HR = 0.63; 95{\%} CI = 0.51-0.77). This population-based cohort study demonstrated that statin use significantly decreased the mortality of PCa patients, and that this risk was inversely associated with the cumulative DDD of simvastatin therapy. The results of this study revealed that statins may be used for drug repositioning and in the development of a feasible approach to prevent death from PCa.",
keywords = "Cohort study, HMG-CoA reductase, Hyperlipidemia, Prostate cancer, Statin",
author = "Chen, {Yu An} and Lin, {Ying Ju} and Lin, {Cheng Li} and Lin, {Hwai Jeng} and Wu, {Hua Shan} and Hsu, {Hui Ying} and Sun, {Yu Chen} and Wu, {Hui Yu} and Lai, {Chih Ho} and Kao, {Chia Hung}",
year = "2018",
month = "3",
day = "22",
doi = "10.3389/fphar.2018.00225",
language = "English",
volume = "9",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "MAR",

}

TY - JOUR

T1 - Simvastatin therapy for drug repositioning to reduce the risk of prostate cancer mortality in patients with hyperlipidemia

AU - Chen, Yu An

AU - Lin, Ying Ju

AU - Lin, Cheng Li

AU - Lin, Hwai Jeng

AU - Wu, Hua Shan

AU - Hsu, Hui Ying

AU - Sun, Yu Chen

AU - Wu, Hui Yu

AU - Lai, Chih Ho

AU - Kao, Chia Hung

PY - 2018/3/22

Y1 - 2018/3/22

N2 - Prostate cancer (PCa) is one of the most commonly diagnosed cancers in the western world, and the mortality rate from PCa in Asia has been increasing recently. Statins are potent inhibitors of 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase and are commonly used for treating hyperlipidemia, with beneficial effects for cardiovascular disease and they also exhibit anti-cancer activity. However, the protective effects of statins against PCa are controversial. In this study, we investigated the effect of two types of statins (simvastatin and lovastatin) and the mortality rate of PCa patients by using the Taiwan National Health Insurance Research Database (NHIRD). A total of 15,264 PCa patients with hyperlipidemia records and medical claims from the Registry of Catastrophic Illness were enrolled. The patients were divided into two cohorts based on their statin use before the diagnosis of PCa: statin users (n = 1,827) and non-statin users (n = 1,826). The results showed that patients who used statins exhibited a significantly reduced risk of mortality from PCa [adjusted hazard ratio (HR) = 0.84, 95% CI = 0.73-0.97]. Analysis of the cumulative defined daily dose (DDD) indicated that patients who were prescribed simvastatin = 180 DDD had a dramatically decreased risk of death from PCa (adjusted HR = 0.63; 95% CI = 0.51-0.77). This population-based cohort study demonstrated that statin use significantly decreased the mortality of PCa patients, and that this risk was inversely associated with the cumulative DDD of simvastatin therapy. The results of this study revealed that statins may be used for drug repositioning and in the development of a feasible approach to prevent death from PCa.

AB - Prostate cancer (PCa) is one of the most commonly diagnosed cancers in the western world, and the mortality rate from PCa in Asia has been increasing recently. Statins are potent inhibitors of 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase and are commonly used for treating hyperlipidemia, with beneficial effects for cardiovascular disease and they also exhibit anti-cancer activity. However, the protective effects of statins against PCa are controversial. In this study, we investigated the effect of two types of statins (simvastatin and lovastatin) and the mortality rate of PCa patients by using the Taiwan National Health Insurance Research Database (NHIRD). A total of 15,264 PCa patients with hyperlipidemia records and medical claims from the Registry of Catastrophic Illness were enrolled. The patients were divided into two cohorts based on their statin use before the diagnosis of PCa: statin users (n = 1,827) and non-statin users (n = 1,826). The results showed that patients who used statins exhibited a significantly reduced risk of mortality from PCa [adjusted hazard ratio (HR) = 0.84, 95% CI = 0.73-0.97]. Analysis of the cumulative defined daily dose (DDD) indicated that patients who were prescribed simvastatin = 180 DDD had a dramatically decreased risk of death from PCa (adjusted HR = 0.63; 95% CI = 0.51-0.77). This population-based cohort study demonstrated that statin use significantly decreased the mortality of PCa patients, and that this risk was inversely associated with the cumulative DDD of simvastatin therapy. The results of this study revealed that statins may be used for drug repositioning and in the development of a feasible approach to prevent death from PCa.

KW - Cohort study

KW - HMG-CoA reductase

KW - Hyperlipidemia

KW - Prostate cancer

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=85044349588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044349588&partnerID=8YFLogxK

U2 - 10.3389/fphar.2018.00225

DO - 10.3389/fphar.2018.00225

M3 - Article

AN - SCOPUS:85044349588

VL - 9

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - MAR

M1 - 225

ER -